Resumen de Tratamiento anticoagulante con fármacos antivitamina-k
For more than 30 years, the antithromboticprotection with antivitamin-k drugs, of oral administration, has drastically modified the prognosis of many processes associated to an elevated thromboembolic risk. Still today, in some clinical environments such as in the carriers of mechanical valvular prostheses no other drug has proved to be as efficient. It is only from the beginning of this new millenium that some alternative anticoagulant drugs of oral administration are going to be available as possible therapeutic options. However, this efficacy is obscured in part by the hemorrhagic risk derived from the use of antivitamin-k drugs and from the necessary frequent practice of controls. The large variability in the dose-response and the complexity of its pharmacokinetics and its pharmacodynamics make the AVK drugs of difficult handling. To this difficulty, we must add the many others derived from the clinical particularities of each patient. Frequently, the treatment must be individualized by evaluating both risks and benefits. This revision is intended to provide a practical perspective of what is currently the handling of antivitamin-k drugs
